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ABSTRACT
Delafloxacin (formerly WQ-3034, ABT492, RX-
3341) is a novel fluoroquinolone chemically
distinct from currently marketed fluoro-
quinolones with the absence of a protonat-
able substituent conferring a weakly acidic
character to the molecule. This property results
in increased intracellular penetration and
enhanced bactericidal activity under acidic
conditions that characterize the infectious
milieu at a number of sites. The enhanced
potency and penetration in low pH environ-
ments contrast what has been observed for
other zwitterionic fluoroquinolones, which
tend to lose antibacterial potency under acidic
conditions, and may be particularly advanta-
geous against methicillin-resistant Staphylococ-
cus aureus, for which the significance of the
intracellular mode of survival is increasingly
being recognized. Delafloxacin is also unique in
its balanced target enzyme inhibition, a prop-
erty that likely explains the very low frequen-
cies of spontaneous mutations in vitro.
Delafloxacin recently received US Food and
Drug Administration approval for the treatment
of acute bacterial skin and skin structure infec-
tions and is currently being evaluated in a phase
3 trial among patients with community-ac-
quired pneumonia. In the current era of a
heightened awareness pertaining to collateral
ecologic damage, safety issues and antimicro-
bial stewardship principles, it is critical to
describe the unique properties of delafloxacin
and define its potential role in therapy. The
purpose of this article is to review available data
pertaining to delafloxacin’s biochemistry,
pharmacokinetic/pharmacodynamics charac-
teristics, in vitro activity and potential for
resistance selection as well as current progress in
clinical trials to ultimately assist clinicians in
selecting patients who will benefit most from
the distinctive properties of this agent.
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INTRODUCTION
Fluoroquinolones are among the most com-
monly prescribed antibiotics, accounting for 23
million and 3.8 million oral and injectable pre-
scriptions in the US in 2011, respectively [1, 2].
Attractive features of this class include their
favorable pharmacokinetic (PK) properties,
broad spectrum of activity and clinical efficacy
for a wide range of commonly encountered
infections [3]. However, paralleling the wide-
spread use of fluoroquinolones has been an
alarming increase in the prevalence of fluoro-
quinolone resistance among clinically relevant
pathogens, underscoring the critical need to
consider antimicrobial stewardship principles
when defining the place in therapy of novel
agents to ensure their utility is not short lived
[4, 5].
Delafloxacin (formerly WQ-3034, ABT492,
RX-3341), a novel dual-targeting anionic fluo-
roquinolone with useful in vitro activity against
methicillin-resistant Staphylococcus aureus
(MRSA), recently received US Food and Drug
Administration (FDA) approval for the treat-
ment of acute bacterial skin and skin structure
infections (ABSSSIs) and is currently being
evaluated in a phase 3 trial for the treatment of
community-acquired pneumonia (CAP) [6].
Fluoroquinolones have not traditionally been
among the first-line options for ABSSSI; how-
ever, delafloxacin’s unique structural and
chemical characteristics, which result in
enhanced potency and intracellular penetration
under acidic conditions, suggest it has the
potential to fill a distinctive therapeutic niche
for certain difficult-to-treat infections [7]. Fur-
thermore, its dual targeting mechanism may
serve to limit the emergence of resistance [8].
The purpose of this article is to critically review
available data pertaining to delafloxacin’s bio-
chemistry, pharmacokinetic/pharmacodynam-
ics (PK/PD) characteristics, in vitro activity and
potential for resistance selection as well as cur-
rent progress in clinical trials to ultimately
delineate future research priorities and assist
clinicians in selecting patients most likely to
benefit from the distinctive properties of this
agent.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
Data Sources
Literature searches of MEDLINE (1946 to July
2017) and EMBASE (1974 to July 2017) were
conducted using the search terms ‘‘ABT-492,’’
‘‘WQ-3034,’’ ‘‘RX-3341’’ and ‘‘delafloxacin.’’
Results were limited to articles available in
English. Additional citations were identified
from the references of relevant literature. Cur-
rent trials focusing on delafloxacin were iden-
tified from clinicaltrials.gov. FDA review
documents for the ABSSSI indication were also
examined. Lastly, data were obtained from
conference proceedings and published
abstracts.
CHEMISTRY AND MECHANISM
OF ACTION
The fluoroquinolone class of antibiotics exerts
antimicrobial activity by inhibiting the two key
enzymes, DNA gyrase and topoisomerase IV,
which are essential for replication [9]. Although
all fluoroquinolones in clinical use are active
against both enzymes, they differ in relative
inhibitory potency, with DNA gyrase as the
more sensitive target among gram-negative
bacteria and topoisomerase IV as the preferen-
tial target among gram-positive pathogens [9].
Delafloxacin demonstrates more balanced
activity against both enzymes [8]. In theory,
equipotent enzyme inhibition should serve to
limit resistance selection since double muta-
tions are relatively rare genetic events [10].
Delafloxacin demonstrates minimum inhi-
bitory concentrations (MICs) that are consis-
tently three- to five-fold lower than comparator
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fluoroquinolones against gram-positive organ-
isms. This is thought to be derived in part from
its greater affinity for DNA gyrase compared
with other fluoroquinolones. Because DNA
gyrase acts ahead of the replication fork to
remove positive supercoils, it inhibits DNA
replication more rapidly than the interaction
with topoisomerase IV, which acts behind it
and, as noted, is the preferential target of com-
parator fluoroquinolones [11]. Delafoxacin’s
increased potency against gram-positive bacte-
ria is also related to its specific shape, size and
polarity [12]. Distinguishing structural charac-
teristics include the presence of a sizable sub-
stituted heteroaromatic ring at N1, the absence
of a basic group at C7 and weak polarity defined
by the chlorine atom at C8 (Fig. 1) [12]. The
heteroaromatic ring at N1 increases the solvent-
accessible surface area, and collaboration
between this large substituent and the weakly
polar group at C8 is thought to influence
potency against quinolone-resistant gram-posi-
tive bacteria [12]. It is hypothesized that this C8
substitution could also reduce second-step
resistance development in S. aureus [13, 14]. The
absence of a basic group at C7 gives delafloxacin
an anionic character at neutral pH [7]. This
latter characteristic is unlike the majority of
other fluoroquinolones, which exist as zwitte-
rions at physiologic pH [7]. Under the acidic
conditions that characterize the local environ-
ment at many infection sites (urinary tract,
abscess fluid, decubitis ulcers, epithelial lining
fluid and phagolysosomes of infected cells),
delafloxacin exists predominantly in the neutral
form, which favors uptake by both eukaryotic
cells and bacteria [7]. This is accompanied by
increased activity against both extra- and
intracellular pathogens, in particular S. aureus,
and contrasts what has been observed for other
agents (fluoroquinolones, macrolides, amino-
glycosides), which lose antibacterial potency
under acidic conditions [7]. Delafloxacin MICs
against a diverse range of gram-negative and -
positive organisms decrease four- to seven-fold
as pH in the surrounding media is reduced from
7.2 to 5.5 [15]. The reduction in MICs are most
pronounced among gram-positive bacteria [15].
MICROBIOLOGY
The in vitro activity of delafloxacin and com-
parator fluoroquinolones against a diverse range
of gram-positive and -negative bacteria are pre-
sented in Tables 1 and 2. Minimum inhibitory
concentration (MIC90, range) values are repre-
sentative of pooled data from studies conducted
with delafloxacin with preference for studies
conducted using isolates collected within the
last 5 years [16, 17]. Standard MIC determina-
tion methods are conducted under neutral pH
conditions, and these values may give a con-
servative estimate of delafloxacin activity under
acidic physiologic conditions.
Among contemporary S. aureus isolates
(MSSA and MRSA), delafloxacin MIC50/90 values
were B 0.004/0.25 mg/l, respectively [18–20].
For a number of bacterial species, including S.
aureus, delafloxacin MICs were bimodal
(0.002–0.003 and 0.06–4 mg/l), presumably
because of existing fluoroquinolone resistance
within the population [20]. Applying the FDA S.
aureus delafloxacin susceptibility MIC break-
point of 0.25 mg/l to the cumulative MIC values
from a diverse collection of contemporary iso-
lates from US and European medical centers
yields susceptibility rates of 98.7% and 88.0%
for MSSA and MRSA, respectively [6, 19]. The
corresponding levofloxacin susceptibility rates
were 89.8% and 30%, respectively [19].
Fig. 1 Chemical structure of delafloxacin
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Table 1 In vitro activity (MIC, mg/l) of delafloxacin and comparators against aerobic gram-positive bacteria. Adapted from
references [18–20, 23]
Organism Phenotype Delafloxacin Levofloxacin Moxifloxacin
MIC90 Range MIC90 Range MIC90 Range
Staphylococcus aureus All 0.25 B 0.004 to 4 [ 4 B 0.12
to[ 4
MSSA 0.015 B 0.004 to 4 2 B 0.12
to[ 4
MRSA 0.5 B 0.004 to 4 [4 B 0.12
to[ 4
Coagulase-negative
Staphylococci
All 0.5 B 0.004 to 2 1 B 0.12
to[ 4
MSCoNS 0.03 B 0.004 to 1 4 B 0.12
to[ 4
MRCoNS 1 B 0.004 to 2 [ 4 B 0.12
to[ 4
Enterococcus faecalis All 1 B 0.004 to 2 [ 4 0.25
to[ 4
VSE 1 B 0.004 to 2 [ 4 0.25
to[ 4
VRE 1 B 0.008 to 2 [ 4 [ 4
Enterococcus faecium All [ 4 0.008 to[ 4 [ 4 0.5 to[ 4
VSE [ 4 0.008 to[ 4 [ 4 [ 4
VRE [ 4 [ 4 [ 4 [ 4
Streptococcus pneumoniae All 0.03 B 0.004 to
0.25
1 0.5 to[ 4 0.25 B 0.12 to 4
PSSP 0.03 B 0.004 to
0.03
1 0.5 to 1
PISP 0.015 0.008 to 0.15 1 0.5 to 1
PRSP 0.03 0.008 to 0.03 1 0.5 to 1 0.25 B 0.12 to
0.25
MDR 0.015 B 0.004 to
0.12
1 0.5 to[ 4 0.25 B 0.12 to 4
Ceftriaxone non-
susceptible
NR B 0.004 to
0.015
NR 1 to 2 B 0.12 to
0.25
Levofloxacin resistant 0.5 0.015 to 1 32 2 to 32 4 0.25 to[ 4
Streptococcus pyogenes 0.015 B 0.004 to
0.03
1 0.25
to[ 4
0.25 B 0.12 to
0.5
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McCurdy et al. recently evaluated the activ-
ity of delafloxacin against a global collection of
S. aureus isolates (n = 687) from skin and skin
structure infections, of which 34% demon-
strated the levofloxacin-resistant phenotype
[18]. Among levofloxacin-susceptible strains,
delafloxacin showed excellent in vitro activity,
and MIC values were not affected by the
methicillin-resistant phenotype (MIC90
0.008 mg/l for both MSSA and MRSA). Dela-
floxacin maintained increased activity against
levofloxacin-resistant MSSA and MRSA isolates;
however, the MIC90 values were increased
32-fold (0.25 mg/l) compared with levofloxacin-
susceptible strains [18], which does raise ques-
tions pertaining to the risk of selecting resistant
mutants during treatment, particularly in high
inoculum S. aureus infections. Resistance selec-
tion studies have indeed demonstrated fewer
passages are required to select mutants with
increased MICs among fluoroquinolone-resis-
tant S. aureus strains compared with sensitive
strains [20]. In the study by McCurdy et al., only
three (0.4%) levofloxacin-resistant MRSA iso-
lates had MIC values above the current dela-
floxacin S. aureus breakpoint [18].
Delafloxacin also demonstrated potent
activity against S. pneumoniae, and, similar to
earlier respiratory fluoroquinolones, its activity
extends to strains displaying penicillin-resistant
or ceftriaxone non-susceptible phenotypes
[19–22]. In a 2014 surveillance study, all Euro-
pean and 98% of US S. pneumoniae isolates were
inhibited by delafloxacin B 0.03 mg/l [19].
These values are similar to those obtained in a
bacterial respiratory surveillance program con-
ducted 12 years earlier throughout Canada
(CROSS), suggesting that delafloxacin, like
other respiratory fluoroquinolones but in con-
trast to ciprofloxacin, has maintained its
potency against S. pneumoniae despite the
selective pressure of fluoroquinolone use during
the intervening period [21]. Approximately 1%
of isolates in the US/European surveillance
study displayed a levofloxacin-resistant
Table 1 continued
Organism Phenotype Delafloxacin Levofloxacin Moxifloxacin
MIC90 Range MIC90 Range MIC90 Range
Streptococcus agalactiae 0.03 B 0.004 to
0.5
1 0.25
to[ 4
0.25 B 0.12
to[ 4
Streptococcus dysgalaciae 0.015 B 0.004 to
0.03
1 0.25
to[ 4
0.25 B 0.12 to
0.25
Viridans group
Streptococci
0.06 B 0.004 to 2 2 B 0.12
to[ 4
0.25 B 0.12 to 4
Streptococcus anignosus
group
0.015 0.008 to
0.015
0.5 0.5
Streptococcus mitis group 0.06 0.03 to 0.06 2 1 to 2
Listeria monocytogenes 0.12 0.06 to 0.12 1 1
MIC minimum inhibitory concentration, MRCoNS methicillin-resistant coagulase-negative staphylococcus, MRSA
methicillin-resistant Staphylococcus aureus, MSCoNS methicillin-susceptible coagulase-negative staphylococcus, MSSA
methicillin-susceptible Staphylococcus aureus, NA not applicable, NR not reported, PISP penicillin-intermediate Streptococcus
pneumoniae, PRSP, penicillin-resistant Streptococcus pneumoniae, PSSP penicillin-susceptible Streptococcus pneumoniae, VRE
vancomycin-resistant enterococcus, VSE vancomycin-susceptible enterococcus
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Table 2 In vitro activity (MIC, mg/l) of delafloxacin and comparators against aerobic gram-negative bacteria. Adapted
from references [11, 18–20, 23, 24]
Organism Phenotype Delafloxacin Levofloxacin Ciprofloxacin
MIC90 Range MIC90 Range MIC90 Range
Escherichia coli All 4 B 0.004
to[ 4
[ 4 B 0.12
to[ 4
[ 4 B 0.03
to[ 4
ESBL [ 4 0.008
to[ 4
[ 4 B 0.12
to[ 4
[ 4 B 0.03
to[ 4
Klebsiella pneumoniae All [ 4 0.015
to[ 4
[ 4 B 0.12
to[ 4
ESBL [ 4 0.06 to[ 4 [ 4 B 0.12
to[ 4
Klebseilla oxytoca 0.12 0.03 to 1 B 0.12 B 0.12 to
1
0.06 B 0.03
to[ 4
Proteus mirabilis All 2 0.015
to[ 4
[ 4 B 0.12
to[ 4
[ 4 B 0.03
to[ 4
ESBL [ 4 2 to[ 4 [ 4 [ 4
Enterobacter spp. 1 B0.004
to[ 4
0.5 B 0.12
to[ 4
0.25 B 0.03
to[ 4
Citrobacter spp. 2 0.008
to[ 4
0.5 B 0.12
to[ 4
0.5 B 0.03
to[ 4
Serratia spp. 2 0.03 to[ 4 1 B 0.12
to[ 4
1 B 0.03
to[ 4
Providencia spp. 0.12 0.008 to 0.5 0.25 0.12 to
0.25
Morganella morganii 4 0.12 to 4 [ 4 B 0.12
to[ 4
Proteus spp. Indole-positive 4 0.008
to[ 4
[ 4 B 0.12
to[ 4
[ 4 B 0.03
to[ 4
Salmonella spp. 0.06 0.008 to 0.5 0.06 0.015 to 1 0.015 0.002 to
0.25
Shigella spp. NR 0.002 to
0.008
NR 0.004 to
0.015
Pseudomonas aeruginosa [ 4 0.015
to[ 4
[ 4 B 0.12
to[ 4
[4 B 0.03
to[ 4
Acinetobacter baumannii–A.
calcoaceticus
[ 4 0.015
to[ 4
[ 4 B 0.12
to[ 4
[4 0.06
to[ 4
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phenotype (MIC[ 4 mg/l), and all were inhib-
ited by delafloxacin B 0.25 mg/l [19].
Delafloxacin is also very active against gram-
negative respiratory pathogens. Haemophilus
influenzae andMoraxella catarrhalisMIC90 values
were B 0.004 and 0.008 mg/l, respectively [22].
Due to the paucity of clinical data pertaining to
outcomes with the use of delafloxacin for the
treatment of respiratory tract infections at this
time, the clinical breakpoints for these three
pathogens have not yet been established.
The MIC90 value of contemporary Enterococ-
cus faecalis isolates from both clinical and
surveillance studies was 1 mg/l with a range
of B 0.004 to 2 mg/l (Table 1) [18–20, 23].
Among levofloxacin-resistant E. faecalis isolates,
delafloxacin’s MIC50/90 values were 0.25 and
8 mg/l, respectively [23]. In the absence of
clinical efficacy or PK/PD studies conducted
with E. faecalis, the interpretive breakpoint
of B 0.12 mg/l was established by the FDA,
which is many fold lower than the observed
MIC90 values [20]. As shown in Table 1, dela-
floxacin is not expected to have useful activity
against E. faecium (MIC90[4 mg/l) [19, 20].
The in vitro activity of delafloxacin and flu-
oroquinolone comparators against a broad
range of contemporary aerobic gram-negative
bacteria is presented in Table 2. As shown,
delafloxacin MIC90 values for E. coli and Kleb-
siella pneumoniae exceed the clinical breakpoint
of B 0.25 mg/l by 16-fold and[ 16-fold,
respectively [19, 20]. The levofloxacin-resistant
phenotype was observed in approximately 30%
and 20% of isolates, respectively, in these
studies [19, 20]. In the surveillance study by
Pfaller et al., delafloxacin susceptibility rates
among US E. coli and K. pneumoniae isolates
were 65% and 78%, respectively [19]. Among
isolates with the ESBL phenotype, susceptibility
rates were just 17.3% and 5.7%, respectively
[19]. Against Enterobacter spp., delafloxacin
appears less active than levofloxacin. Dela-
floxacin demonstrated more potent activity
against K. oxytoca with MIC90 values of 0.12 mg/
l [19, 20]. As shown in Table 2, delafloxacin
activity against Pseudomonas aeruginosa (MIC50/
90 0.25/4 mg/l; 65% susceptible) is similar to
comparator anti-pseudomonal fluoro-
quinolones [19, 20].
Clinical experience with the indicated gram-
negative pathogens has been very limited with
most non-surveillance isolates cultured from
poly-microbial infections in ABSSSI studies
Table 2 continued
Organism Phenotype Delafloxacin Levofloxacin Ciprofloxacin
MIC90 Range MIC90 Range MIC90 Range
Burkholder cepacia Ciprofloxacin
susceptible
NR 0.25 NR 1 NR 1
Ciprofloxacin
resistant
16 0.25 to 16 [ 128 2 to[ 128 [ 128 2 to[ 128
Haemophilus influenza 0.004 B 0.001 to
0.25
0.03 0.008
to[ 2
0.015 0.004
to[ 2
Moraxella catarrhalis 0.008 0.004 to
0.015
0.06 0.03 to
0.12
0.06 0.015 to
0.06
Neisseria gonorrhea 0.06 0.125 16 0.004
to[ 16
ESBL extended-spectrum beta-lactamase, MIC minimum inhibitory concentration, NA not applicable, NR not reported
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[18, 20]. If the use of delafloxacin is contem-
plated for infections in which gram-negative
bacilli are common pathogens, additional clin-
ical data are needed to better determine how
MIC values measured by standard methods
should inform treatment decisions.
Delafloxacin has shown excellent in vitro
activity against Neisseria gonorrheae including
ciprofloxacin-resistant and multidrug-resistant
(MDR) strains (Table 2) [24]. Against a panel of
N. gonorrheae clinical isolates collected from
medical centers across the US during 2012 to
2015, including 67.5% with the ciprofloxacin-
resistant phenotype, the delafloxacin MIC90
value was 0.125 mg/l [24]. Lessons from the past
however have shown that findings from in vitro
studies may not be entirely predictive of clinical
outcomes for N. gonorrheae infection [25].
Unfortunately, a phase 3 trial comparing a sin-
gle oral dose of delafloxacin (900 mg) to ceftri-
axone for the treatment of uncomplicated
gonorrhea (NCT02015637) was terminated
early in 2015 for reasons of insufficient efficacy
following an independent interim review [26].
The in vitro activity of delafloxacin against
Mycobacterium tuberculosis and M. avium was
evaluated in a single study [27]. Delafloxacin
was more efficacious than levofloxacin at
inhibiting intracellular macrophage growth of
M. tuberculosis. It is hypothesized that this
observation may be related to improved deliv-
ery of delafloxacin to the phagosomes of MM6-
M/s that engulf bacteria. Additionally, the
potentiation of delafloxacin’s antimicrobial
activity under the acidic conditions that are
characteristic of the macrophage phagosomes
that engulf mycobacterial pathogens may be
particularly advantageous [27]. Further support
for delafloxacin’s ability to accumulate and
exert antibacterial activity within mammalian
cells comes from demonstrations of its activity
against Chlamydia spp., an obligate intracellular
pathogen, with MICs ranging from 0.03 to
0.06 mg/l [11].
Few studies have evaluated the activity of
delafloxacin against clinically relevant anaero-
bic organisms [11, 28]. Potent activity was
demonstrated against Bacteroides fragilis in par-
ticular in one study, with an MIC90 value of
0.125 mg/l [28]. Caution is advised when
interpreting the findings because isolates were
collected nearly 15 years ago, and in the inter-
vening period fluoroquinolone resistance
among key anaerobic bacteria has increased
significantly [16, 29]. More recent US surveil-
lance data testing isolates collected during 2010
to 2012 have shown much lower susceptibility
rates for moxifloxacin against key anaerobic
species [16, 29]. Although the potential for
cross-resistance among anaerobic species for
delafloxacin and other fluoroquinolones has
not been explored, high levels of cross-resis-
tance have been documented between earlier
fluoroquinolones.
More contemporary data pertaining to dela-
floxacin’s activity against Clostridium difficile
has been presented. Vernon et al. investigated
the in vitro activity of delafloxacin and com-
parator agents against prevalent C. difficile
ribotypes (RTs) [30]. Delafloxacin’s geometric
mean (GM) MIC overall was 0.37 mg/l. Large
differences in activity were observed for isolates
belonging to the hypervirulent RT027 com-
pared with non-RT027 (GM MIC 4.0, 0.13 mg/l,
respectively), suggesting delafloxacin shares in
the universal fluoroquinolone class resistance in
this troublesome strain [30].
PHARMACOKINETICS
The PK properties of delafloxacin have been
evaluated in phase 1 and 3 studies utilizing
single and multiple ascending doses ranging
from 300 to 1200 mg (IV) and 50 to 1600 mg
(oral) [31–33]. As shown in Table 3, at steady
state, delafloxacin, administered as 300 mg IV
every 12 h, achieves a maximum serum con-
centration (Cmax) of 9.29 mg/l and total expo-
sure (AUC from 0 to 12 h, AUCs) of 23.4 mg h/l.
The bioavailability of the tablet formulation is
59%, which is lower than that of other fluoro-
quinolones such as levofloxacin and moxi-
floxacin (99% and 92%, respectively; Table 3);
however, the AUCs of delafloxacin 450 mg
administered orally (20.6 mg h/l) is comparable
to that achieved with a labeled IV dose of
300 mg [6, 32–34]. Both the IV and oral for-
mulations demonstrate approximate dose pro-
portional increases in exposure following single
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doses ranging up to 1200 and 1600 mg, respec-
tively [32, 33]. The Cmax is reduced 20%, and
the time to Cmax (Tmax) is doubled when dela-
floxacin tablets are administered with food
compared with the fasting state. However, total
delafloxacin exposure (AUCs) is similar when
administered with or without food; thus, PK
changes secondary to food intake around the
time of dosing are not expected to affect clinical
outcomes [32, 33].
Delafloxacin volumes of distribution have
ranged from 35 to 48 l across studies. Protein
binding (primarily to albumin) is approximately
84% (Table 3) [6, 33–35]. Delafloxacin shares
the fluoroquinolone class characteristic of high
pulmonary distribution with a 13:1 mean pen-
etration ratio into the epithelial lining fluid vs.
free plasma concentration [36]. Data pertaining
to the distribution characteristics of dela-
floxacin in other tissues have not been reported
at this time.
Table 3 Pharmacokinetic parameters of delafloxacin and comparator fluoroquinolones. Adapted from references
[6, 33–35]
Parameter Delafloxacin IV
(300 mg, every
12 h)
Delafloxacin PO
(450 mg, every
12 h)
Levofloxacin PO
(750 mg, every
24 h)
Ciprofloxacin PO
(500 mg, every
12 h)
Moxifloxacin PO
(400 mg, every
12 h)
Vd (l) 35–48 100 84–189
a 119–189a
Cmax (mg/l) 9.29 7.45 8.6 3.0 4.5
fCmax (mg/l) 1.49 1.19 5.3–6.5 1.8–2.4 2.25–3.15
AUC0–s
(mg h/l)
30.8 23.4 90.7 13.7 48
fAUC0–s
(mg h/l)
4.93 3.74 56.2–68.9 8.2–11.0 24–33.6
AUC24 (mg h/
l)
61.6 46.8 90.7 27.4 48
fAUC24 (mg h/
l)
9.86 7.48 56.2–68.9 16.4–22.0 24–33.6
Protein binding 84% 24–38% 20–40% 30–50%
T1/2 (h) 3.7
b 4.2–8.5 8.8 4–6 10–14
Elimination
(urine:feces)
64.5%:28.4%b 50.2%:47.7% 87%:4% 57%:20–35% 20%:25%
Oral
bioavailability
N/A 58.8% 99% 70% 92%
Metabolism Glucuronidationc Limited? Oxidation? Sulfation,
glucuronidation
Vd volume of distribution, Cmax peak serum concentration, fCmax free peak concentration, AUC0–s area under the curve
over the dosing interval, fAUC0-s free area under the curve over the dosing interval, AUC24 area under the curve over 24 h,
fAUC24 free area under the curve over 24 h, T1/2 half- life
a Based on a 70-kg adult
b After a single dose
c No significant circulating metabolites
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Delafloxacin is primarily metabolized
through glucuronidation, with oxidative meta-
bolism accounting for approximately 1% of the
administered dose, suggesting a low potential
for drug interactions. The predominant route of
elimination is renal (50–65%) with the remain-
der of elimination occurring in the feces as
unchanged drug. Delafloxacin’s half-life was
3.7 h following a single IV 300 mg dose and
ranged from 4.2 to 8.5 h following multiple oral
doses [6, 33, 37].
PK parameters of delafloxacin have been
examined in patients with varying degrees of
renal impairment [33]. Delafloxacin exposure
has consistently been shown to increase with
decreasing renal function; however, clinically
important differences are not apparent until the
estimated glomerular filtration rate (eGFR) as
calculated using the Modification of Diet in
Renal Disease equation (MDRD) is under 30 ml/
min/1.73 m2. The AUCs increased 1.8-fold in
patients with severe renal impairment (eGFR
15–29 ml/min/1.73 m2) following a single
300 mg IV dose. The corresponding fold chan-
ges in total exposure among patients with end-
stage renal disease (ESRD) when delafloxacin
was administered before and after hemodialysis
(HD) were 2.1 and 2.6, respectively. Decreased
plasma protein binding has also been observed
in subjects with severe renal impairment and
ESRD (80% and 75%, respectively). Based on
population PK simulations, an adjusted dose of
200 mg IV every 12 h is recommended for
patients with severe renal impairment [6, 33].
The lower dose also reduces the risk for adverse
renal effects secondary to sulfobutylether-beta-
cyclodextrin (SBECD, an excipient in the IV
formulation) accumulation [33].
Decreasing renal function does not appear to
greatly impact the exposure of delafloxacin
tablets; drug exposure was 1.5-fold higher in
subjects with severe renal impairment following
oral administration (450 mg) compared with
subjects with normal renal function. A dosing
regimen of 450 mg IV every 12 h produced
exposures in patients with normal renal func-
tion similar to those achieved in patients with
severe renal impairment that were administered
the 450-mg oral dose, and tolerability was
acceptable at these exposures [33]. Thus, dosage
adjustment of the oral formulation for patients
with severe renal impairment is not recom-
mended. Currently, there are no explicit labeled
recommendations for dosing in patients main-
tained on HD. Twenty percent of the drug is
removed during a 4-h HD session [6].
The PK profile of delafloxacin has been
evaluated in subjects with varying degrees of
hepatic impairment. Total AUC values were
similar in patients with normal, mild and
moderate hepatic function. Higher PK variabil-
ity was observed in patients with severe hepatic
impairment, and total exposure was increased
approximately 40% compared with controls.
These differences are unlikely to be clinically
important, and dosage adjustment in this pop-
ulation is not recommended [33].
PHARMACODYNAMICS
Similar to other fluoroquinolones, delafloxacin
exhibits concentration-dependent antimicro-
bial activity, and the unbound drug AUC over
24 h divided by the MIC of the pathogen
(fAUC24/MIC) is the PK/PD parameter most
closely associated with delafloxacin activity
[33, 38]. The PD target value for delafloxacin
against S. aureus was determined in a series of
experiments using the murine neutropenic
thigh infection model [33]. Animals were inoc-
ulated with 106 CFU of MSSA or MRSA pos-
sessing delafloxacin MICs ranging from 0.004 to
0.006 mg/l and 0.016 to 0.8 mg/l, respectively.
Delafloxacin (1.25 to 320 mg/kg) was adminis-
tered as a single dose, and the bacterial burden
was determined 24 h after dosing. The median
fAUC24/MIC ratios associated with net bacterial
stasis and a 1-log10 CFU reduction were 9.3 and
14.3, respectively. Utilizing a murine lung
infection model for collection of MSSA and
MRSA isolates with MICs ranging from 0.004 to
0.008 mg/l, Andes et al. documented substan-
tially lower median target ratios (stasis 1.74 and
1-log10 CFU reduction 7.92) [39]. Similarly, the
median fAUC24/MIC ratio of delafloxacin to
achieve either stasis or 1-log10 CFU reduction in
a neutropenic murine lung model by Thabit
et al. utilizing MSSA isolates (MIC
0.002–0.52 mg/l) was 0.4 [36]. However, the
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corresponding target ratios for MRSA isolates
with baseline MICs of 0.25–1 mg/l were mark-
edly higher in this study (stasis 8.1 and 1-log10
CFU reduction 24.7) and more closely aligned
to those generally quoted for fluoroquinolones
against gram-positive cocci (fAUC24/MIC C 25)
[36, 38]. Thus, it appears that PK/PD targets for
delafloxacin may differ between stains, pheno-
types and site of infection.
Similar experiments were also conducted to
determine the threshold fAUC24/MIC ratios
associated with efficacy against E. coli and P.
aeruginosa. Findings indicated mean fAUC24/
MIC targets for bacterial stasis and a 1-log10 CFU
reduction for E. coli were 14.5 and 26.2,
respectively, while the corresponding fAUC24/
MIC targets for P. aeruginosa were 3.8 and 5.0,
respectively.
Staphylococcus aureus is frequently associated
with biofilm-related infections, which are par-
ticularly difficult to treat because antibiotics
tend to be much less active against bacteria
embedded in biofilm compared with those in
the planktonic state [40]. The increased potency
of delafloxacin under acidic conditions may be
particularly advantageous in this setting [7].
Utilizing an in vitro PD model of mature S.
aureus biofilms, Bauer et al. reported that dela-
floxacin reduced both MSSA and MRSA biofilm
viability by at least 50% at clinically achievable
concentrations [41]. Delafloxacin, oxacillin
(MSSA) and daptomycin were the most effica-
cious among a panel of nine anti-staphylococ-
cal agents. The interpretation of these findings
is somewhat hampered by the use of reference S.
aureus strains displaying MICs that are 4-
(MSSA) and 125-fold (MRSA) lower than MIC90
values documented in contemporary surveil-
lance studies [41].
In a second biofilm study using MSSA and
MRSA with a broader range of delafloxacin MIC
values (0.004–0.125 mg/l), delafloxacin dis-
played potent activity at clinically achievable
concentrations against five of the seven isolates
tested [42]. Investigators did not account for
delafloxacin protein binding (84%) when con-
sidering achievable Cmax values in vivo
however. The penetration of delafloxacin
within the biofilm was observed to range from
0.62% to 51.8% and was generally greater in
biofilms with lower pH values [42].
Renal abscesses involving S. aureus are chal-
lenging to treat with currently available agents
because of the presence of a large proportion of
bacteria in the stationary phase of growth, and
the local environment is usually characterized
by low pH values [7]. Ding et al. investigated the
comparative activity of delafloxacin and moxi-
floxacin against renal abscesses formed by a
community-associated MRSA strain (MW2) in a
murine model of systemic infection [43]. Both
delafloxacin and moxifloxacin reduced the
bacterial load in renal abscesses compared with
controls. The reduction of the bacterial burden
by delafloxacin was significantly greater than
that by moxifloxacin [43].
Delafloxacin has also demonstrated
increased activity against gram-negative patho-
gens under acidic experimental conditions. So
et al. examined the effect of urine matrix and its
varying pH on the activity of delafloxacin and
ciprofloxacin against 16 MDR urogenic E. coli
and K. pneumoniae [44]. All isolates were resis-
tant to both ciprofloxacin (MIC 32 to[ 64 mg/
l) and delafloxacin (MIC 2–16 mg/l) at baseline
when measured in standard media. Similar to
results obtained for delafloxacin against gram-
positive pathogens tested under acidic experi-
mental conditions [7], delafloxacin MICs
decreased by 1–3 doubling dilutions in 53% and
68% of observations for E. coli and K. pneumo-
niae, respectively, when MIC testing was per-
formed in acidic urine. By contrast, MICs for
ciprofloxacin remained relatively unchanged
across the range of pH values tested [7]. Even
with the maximal MIC reductions when using
urine as the test media, most isolates would
continue to demonstrate MICs far above the
current delafloxacin Enterobacteriaceae inter-
pretive breakpoint of B 0.25 mg/l; thus, the
clinical implications of this study as relates to
the potential utility of delafloxacin in the
treatment of MDR Enterobacteriaceae are not
entirely clear [6, 44].
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RESISTANCE
Resistance to fluoroquinolones most commonly
involves step-wise chromosomal mutations in
the quinolone resistance-determining regions
(QRDR) of DNA gyrase (gyrA) and/or topoiso-
merase IV (parC/grlA). Overexpression of efflux
pumps and decreased uptake secondary to
reduced expression of outer membrane porins
may also contribute to chromosomal resistance
[9, 45]. Finally, plasmid-mediated fluoro-
quinolone resistance is an emerging concern
[45].
Delafloxacin maintains clinically useful
activity against a range of bacteria displaying
the quinolone-resistant phenotype secondary to
single and double mutations in the QRDR as
well as efflux pump expression. The ability of
delafloxacin to select for spontaneous muta-
tions within the QRDR or efflux pump gene loci
in vitro has been investigated in a number of
studies using both naı¨ve strains and those with
pre-existing mutations. Remy et al. conducted a
series of spontaneous resistance selection
experiments using four strains of S. aureus, three
of which carried pre-existing mutations in the
QRDR [8]. The observed resistance frequencies
were low (6.0 9 10-9 to\9.5 9 10-9) for dela-
floxacin at two times the baseline MIC and
similar to those demonstrated for moxifloxacin
[8]. The resistance frequencies of both drugs
were substantially less than that of levofloxacin.
Notably, no delafloxacin-resistant strains could
be isolated from the strain that had no pre-ex-
isting QRDR mutations [6]. The minimum pro-
tective concentration in the present study
ranged from one to four times the initial MIC
for all quinolones tested. Delafloxacin-resistant
mutants maintained their reduced susceptibility
following passage in drug-free media for 7 days,
suggesting a stable phenotype [8, 46].
Whole-genome sequencing characterized the
nature of the mutations of the resultant vari-
ants. Delafloxacin-selected variants with MIC
shifts B 4-fold of the parent strain showed no
genetic changes in the QRDR or the norA loci,
which encodes for the predominant fluoro-
quinolone efflux pump in S. aureus. Mutant
strains with delafloxacin MICs C 8-fold those of
the parent strain were characterized by both
previously described and novel mutations in
gryA and gyrB. Two variant isolates, both with
MICs of 4 mg/l and selected from a parent strain
with pre-existing gyrA and grlA mutations,
showed no changes in the QRDR or the norA
sequence and its surrounding regulatory
regions, suggesting delafloxacin resistance may
arise through previously uncharacterized
mechanisms [8].
CLINICAL EFFICACY
The clinical efficacy of delafloxacin has been
evaluated in phase 2 and phase 3 studies among
patients with ABSSSI as well as phase 2 studies
among patients with acute exacerbation of
chronic obstructive pulmonary disease and CAP
[47–52].
The first clinical study to evaluate dela-
floxacin in the treatment of ABSSSIs was a phase
2 randomized, double-blind, multicenter, dose-
ranging comparative study [48]. Adults with
wound infection, abscess or cellulitis were
enrolled from 14 centers in the US; patients
(n = 150) were randomized to delafloxacin 300
or 450 mg, each administered IV, every 12 h or
tigecycline 100 mg IV once, followed by 50 mg
IV, every 12 h for 5–14 days [48]. S. aureus
comprised nearly 90% of gram-positive patho-
gens, and methicillin-resistance was detected in
71%. Clinical cure rates and microbiologic
eradication rates exceeded 90% in all treatment
groups with no between-group differences.
Kingsley et al. performed the second phase 2
ABSSSI multicenter, randomized, double-blind
trial evaluating delafloxacin (300 mg) versus
linezolid (600 mg) and vancomycin (15 mg/kg,
actual body weight; maximum 1250 mg; target
trough 15–20 mg/l), each administered IV twice
daily for 5–14 days [47]. The addition of blinded
aztreonam was permitted for patients with
gram-negative infections randomized to line-
zolid or vancomycin. In total, 256 patients
comprised the intention-to-treat population
(ITT). S. aureus was the most frequently isolated
organism with 67% of strains displaying the
methicillin-resistant phenotype [47]. Cure rates
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at the follow-up time point (day 14) were 70.4%
in the delafloxacin group compared with 64.9%
in the linezolid group (P = 0.496 vs. dela-
floxacin) and 54.1% in the vancomycin group
(P = 0.031 vs. delafloxacin). The higher cure
rate in the delafloxacin vs. vancomycin group
appeared to be driven by patients with a body
mass index (BMI) C 30 kg/m2 (78.8% vs. 48.8%;
P = 0.009). Among the microbiologically
evaluable population (n = 125), presumed or
documented eradication rates were similar
between groups and ranged from 80.8% to
88.2% [47].
There are several limitations to these studies
that deserve comment. Importantly, as phase 2
trials, they were not designed with a formal pre-
specified hypothesis or powered for any infer-
ential statistical testing. Both trials included a
relatively small number of patients and, as a
consequence, the range of bacterial pathogens
recovered was limited. Furthermore, patients
most at risk for infection with a broader range of
bacterial species (i.e., those who are immuno-
compromised or have severe underlying
comorbidity) and who therefore may stand to
benefit from delafloxacin’s expanded spectrum
of activity, were excluded from the studies. The
MRSA MICs for delafloxacin were considerably
lower than has been observed in recent
surveillance studies [20, 47, 48]. All patients
were enrolled from US centers, which raises the
question of whether the data are applicable
across geographic populations. Finally,
although most patients were treated in the
outpatient setting, the efficacy of the oral for-
mulation of delafloxacin was not evaluated.
To address these limitations as well as fulfill
regulatory drug approval requirements, two
phase 3 studies evaluating delafloxacin for the
treatment of adult patients with ABSSSIs were
initiated in 2013 (NCT01811732/RX-3341-302
and NCT1984684/RX-3341-303, hereafter refer-
red to as study 302 and303, respectively) [51, 52].
Both were multicenter, randomized, double-
blind, non-inferiority studies comparing dela-
floxacin (300 mg) with vancomycin (15 mg/kg
actual body weight) plus aztreonam (2 g), each
administered IV, every 12 h for 5–14 days
[51, 52]. In study 303, a switch to oral dela-
floxacin (450 mg)wasmandated following six IV
doses except for patientswith an eGFR 15–29 ml/
min who were to receive delafloxacin 200 mg IV
every 12 h for all doses [51, 52]. If gram-negative
pathogens were not isolated on the baseline
culture, aztreonamwas discontinued. No similar
de-escalation to targeted therapy occurred for
patients in the delafloxacin arms. Patients with
infections involving prosthetic material or asso-
ciated with human/animal bites, osteomyelitis,
decubitus ulcer, diabetic foot ulcer, septic
arthritis, necrotizing fasciitis or burns cover-
ing C 10% of the body surface area were not eli-
gible for enrollment. Other key exclusion criteria
included severe underlying comorbidity (liver
disease, end-stage renal disease, cardiac disease,
malignancy), history of seizure disorder and
pregnancy or lactation. The primary endpoint in
the two studies was C 20% reduction in lesion
size at 48–72 h in the ITT population. In study
303, enrollment was expanded above the calcu-
lated sample size to enrich for a pre-specified
subgroup analysis by BMI [51, 52].
In total, 660 and 850 patients were ran-
domized in study 302 and 303, respectively. In
both studies, the majority of patients were
enrolled from US centers. The mean age of
participants was approximately 46 and 50 years
in study 302 and 303, respectively. Few patients
aged 65 years and older were enrolled (7% and
20%, respectively). Approximately 80–90% of
patients were Caucasian; African American
patients were under-represented (7% and 20%).
Obese patients (BMI C 30 kg/m2) comprised
32% and 40% of the study populations. Eight to
13% of patients carried a diagnosis of diabetes,
and approximately 1% had severely decreased
renal function (eGFR\ 30 ml/min). Bacteremia
was rare in both studies (2.3%, 2.2%) [51, 52].
The most prevalent pathogen isolated from
the infection site was S. aureus, which was
identified in 66% and 58% of the microbiologic
ITT (MITT) patients in study 302 and 303,
respectively. MRSA accounted for 52% and 36%
of the S. aureus isolates, respectively [51, 52].
Delafloxacin was non-inferior to van-
comycin plus aztreonam for the primary end-
point in both trials. Outcomes at the end of the
therapy time point (14 ± 1 day) were similar,
suggesting a sustained response to treatment in
all groups. Importantly, outcomes at the later
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time points in study 303 are supportive of oral
delafloxacin, which would have been initiated
following assessment of the primary outcome.
Among the MITT population, per pathogen
response rates were generally similar between
treatment groups across all pathogens. Overall,
66% of MRSA isolates were levofloxacin non-
susceptible [51]. Among these isolates, the
delafloxacin MIC90 value was 0.25 mg/l, and the
eradication or presumed eradication rate was
98.6%. One MRSA isolate displayed an MIC of
4 mg/l, and double mutations in both gyrA and
parC were subsequently confirmed. The micro-
biologic response for the patient with this iso-
late was presumed eradicated based on clinical
response. Approximately 15% of isolates recov-
ered were gram-negative. The predominant
gram-negative pathogens were K. pneumoniae
and E. coli. Levofloxacin non-susceptibility was
low among K. pneumoniae (2.2%), and most
were susceptible to delafloxacin (MIC50/90 0.12/
0.25 mg/l). Levofloxacin non-susceptibility was
slightly higher among E. coli, and the dela-
floxacin MIC90 was 4 mg/l [51].
Subgroup analysis by age, sex, race and geo-
graphic region were consistent with the overall
results; however, analysis is limited by the small
number of patients in some subgroups, partic-
ularly those from regions outside of the US and
African American patients [51, 52].
In study 302, an exploratory post hoc anal-
ysis by BMI category suggested a significant
improvement in cure rates at the long-term
follow-up time point among obese patients
assigned to delafloxacin compared with van-
comycin (71.7% vs. 57.5%; treatment difference
14.2%, 95% CI 1.3% to 26.9%) [51, 52]. This
finding however was not subsequently con-
firmed in study 303, which, as noted previously,
was enriched with obese patients to allow for
formal statistical testing of this hypothesis.
Among obese patients the cure rates at the late
follow-up time point were similar (68.3% vs.
71.0%; treatment difference -2.7%, 95%
CI - 11.5% to 6.0%). Information pertaining to
vancomycin trough target attainment has not
been reported for the overall study populations
or by BMI category [51, 52].
Although these studies addressed several
limitations of the phase 2 studies including a
larger number of patients and conducting for-
mal hypothesis testing, they did not expand
knowledge of delafloxacin’s performance
among patients at risk for a broader range of
pathogens. Key populations including the
elderly, those with organ dysfunction, and
those with significant underlying comorbidity
were either excluded or under-represented.
Furthermore, although too few gram-negative
isolates were collected to allow for meaningful
analysis, the high delafloxacin MIC values dis-
played among those that were obtained suggest
delafloxacin may not be an ideal option when
these pathogens are suspected, although, as
noted previously, MIC values determined by
standard methods may underestimate in vivo
activity.
The efficacy of delafloxacin has also been
explored among patients with respiratory tract
infections [49, 50]. Longcor et al. conducted a
phase 2, double-bind, randomized, dose-rang-
ing study comparing three dose ranges of oral
delafloxacin (100, 200, 400 mg daily 9 5 days)
to levofloxacin (500 mg daily 9 7 days) in adult
outpatients diagnosed with ABECB [49]. In
total, 280 patients were randomized with a
mean age of 61 years. Clinical cure rates were
similar in the four groups (69–79%), and no
dose-response trend was identified. Regarding
bacteriologic cure rates, however, outcomes
were improved among patients assigned to
delafloxacin 400 mg compared with the lower
doses. In the phase 2 study evaluating the
clinical and bacteriologic outcomes with
ascending delafloxacin doses (100, 200 or
400 mg once daily for 7 day) among adult out-
patients with CAP (n = 309), clinical and bac-
teriologic cure rates were similar in the 200 and
400 mg groups and slightly lower for the
100 mg group [50].
While the results of these studies are
encouraging and appear to support a role for
delafloxacin in the treatment of bacterial respi-
ratory tract infections, further data from an
ongoing phase 3 study comparing delafloxacin
to moxifloxacin or linezolid for the treatment
CAP (NCT02679573) are required before
definitive conclusions pertaining to its efficacy
for respiratory infections can be made.
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ADVERSE EFFECTS
For many years, fluoroquinolones were consid-
ered a safe and generally well-tolerated class of
antimicrobials [53]. In recent decades, however,
safety concerns have led to restrictions on the
use of fluoroquinolones and, in some instances,
withdrawal of agents from the market [53, 54].
Recently, the FDA advisory committees on
antimicrobial drugs and drug safety concluded
that a risk vs. benefit analysis did not support
the use of these agents in a number of uncom-
plicated infections, and labeling of all marketed
fluoroquinolones has been updated to include
stronger warnings pertaining to the risks serious
adverse effects (AEs) such as tendon rupture,
peripheral neuropathy and central nervous sys-
tem (CNS) disturbances [55]. Distinct differ-
ences among fluoroquinolones with regard to
their safety profile can be predicted in part by
structural differences with structure-AE rela-
tionships based on constituents at specific sites
on the quinolone nucleus [54]. Delafloxacin has
a number of unique structural characteristics,
however, which present challenges when
attempting to predict the potential for serious
AEs by this approach.
As with all fluoroquinolones, the most
commonly reported AEs in phase 3 delafloxacin
trials were gastrointestinal (GI) related (diarrhea
8%, nausea 8%) or mild CNS events [56]. Data
from phase 1 and 2 studies indicate an associa-
tion between GI AEs and higher doses [56].
There does not appear to be a clear fluoro-
quinolone structure-GI AE relationship, but
rather GI AEs are thought to be due to direct GI
irritation and/or indirect CNS effects [53].
Tendinopathies are rare AEs associated with
fluoroquinolones [57]. Although there has not
been a widely accepted structural moiety asso-
ciated with tendinopathy, animal models sug-
gest structural differences at position 7 may play
a role with a methypiperadinyl group causing
the highest number of tendon lesions [57].
Delafloxacin is the only marketed fluoro-
quinolone with a weakly acidic substituent at
this position [58]. Three patients in pooled
phase 3 delafloxacin trials reported tendonitis
[56]. One event was graded as moderate in
severity, and all other events were considered to
be mild. Predisposing factors such as concomi-
tant steroid use and renal disease were not pre-
sent in any of the affected patients [56].
AEs involving the CNS have generally been
the second most commonly encountered form
of fluoroquinolone toxicity and include a broad
variety of effects ranging from headaches and
dizziness to acute psychosis to seizures [54].
These effects are thought to occur secondary to
fluoroquinolone blockade of GABA receptors
[53, 54]. In vitro experiments suggest that the
delafloxacin concentrations required to inhibit
GABA are many fold above those achieved
clinically [56]. In line with these experimental
observations, headache occurred in just 3% of
delafloxacin-treated patients in pooled phase 3
trials, and other CNS AEs were relatively rare
[56]. No patients in the delafloxacin arms of
phase 3 studies experienced seizures or convul-
sions [56]. One patient who received a higher
than labeled dose of delafloxacin (450 mg IV)
during a phase 2 study experienced a seizure
[56].
Structural differences at positions 1, 5 and 8
of the quinolone nucleus influence the photo-
toxic potential [54]. Fluoroquinolones with a
halogen at position 8 of the nucleus along with
a bulky side chain are well known for their
associated phototoxicity [53]. A methyl group at
position 5 may also contribute [53]. Dela-
floxacin contains a chlorine at position 8 but
lacks a bulky side chain and contains no R5
substituent [58]. A phase 1 study investigating
the photosensitizing potential of delafloxacin
demonstrated findings similar to placebo with
no evidence of phototoxicity in either the low
(200 mg) or high (400 mg) dose arms of dela-
floxacin-treated subjects [56]. By comparison,
more subjects assigned to the positive control
group (lomefloxacin) exhibited both mild and
severe phototoxicity at various wavelengths.
Assessment of the hepatotoxic potential of
delafloxacin is limited by the relatively small
number of patients who have been exposed at
this time. Although case reports of severe liver
injury emerged soon after trovafloxacin was
introduced into the clinic, it was not until
approximately 2.5 million courses of therapy
had been administered that the causal
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relationship was deemed strong enough to
warrant its removal from the market [59]. The
frequency of clinically significant elevations
([5 times the upper limit of normal) of aspar-
tate aminotransferase, alanine aminotransferase
and alkaline phosphatase was 0.3% or less
across delafloxacin groups in phase 3 trials, and
no clinically significant elevations in bilirubin
occurred [56]. These parameters may be poorly
predictive of the potential for drug-induced
hepatotoxicity however.
The main area of interest relating to the
cardiac toxicity of fluoroquinolones is prolon-
gation of the QTc interval [59]. The mechanism
by which this occurs is likely multifactorial, and
an obvious structural moiety that increases the
risk for QTc prolongation has not yet been
identified [54]. Studies of various fluoro-
quinolones have shown a dose-dependent
inhibition of the rapid-acting portion of the
delayed rectifier potassium current, which is
controlled by the human ether-a-go-go gene
(HERG) [60]. Preclinical studies with dela-
floxacin have found that it did not block HERG
currents. In a phase 1 study delafloxacin doses
up to three-fold higher than the currently
labeled dose (900 mg) did not induce clinically
meaningful changes in the QTc, while moxi-
floxacin, which served as the positive control,
produced predicted prolongation of the QTc
interval [56, 61]. In phase 3 studies, no occur-
rences of drug-induced arrhythmias were
reported [56].
Administration of fluoroquinolones has
emerged as one of the most important risk fac-
tors for C. difficile-associated diarrhea (CDAD)
caused by the hypervirulent RT027 strain [62].
In early surveillance studies, delafloxacin
demonstrated potent activity against many
anaerobic species [28]. In particular, it showed
greater in vitro activity against C. difficile than
comparator fluoroquinolones; however, activity
against the RT027 strain was considerably lower
[30]. The impact of delafloxacin, of which
35–50% is eliminated unchanged in the feces,
on bowel flora is unknown at this time. Two
cases of CDAD were reported among patients
enrolled in the delafloxacin arms of phase 2 and
3 studies [56]. Both patients were noted to have
a number of risk factors for CDAD besides
antibiotic exposure [56].
Fluoroquinolones are not known to com-
monly cause harmful effects on the kidneys;
however, the vehicle used to deliver IV dela-
floxacin, SBECD, may be problematic in
patients with renal impairment [63]. A reduced
delafloxacin dose (200 mg IV q12 h) is therefore
recommended in patients with an eGFR \
30 ml/min/1.73 m2 and a switch to oral dela-
floxacin as soon as clinically indicated [6].
To summarize, the available data have not
demonstrated significant safety concerns for
delafloxacin. However, as with all new antibi-
otics, assessment of safety is limited by the
small number of healthy subjects and patients
to whom it has been administered. Exclusion
criteria in completed phase 3 trials also limit the
generalizability of safety findings to patients
who may be more likely to receive this agent in
the clinic, i.e., those with pre-existing organ
dysfunction and a higher degree of baseline
comorbidities. Nevertheless, the additional
quasi-experimental data, which included posi-
tive controls for two important class AEs, pho-
totoxicity and QTc prolongation, are reassuring.
DRUG INTERACTIONS
Like other fluoroquinolones, delafloxacin forms
insoluble chelation complexes with multivalent
cations in the GI tract resulting in a substantial
decrease in oral absorption of the antibiotic,
and concomitant administration should be
avoided [6]. At clinically relevant concentra-
tions, delafloxacin does not inhibit cytochrome
P450 isoenzymes 1A2, 2A6, 2B6, 2C8, 2C9,
2C19, 2D6, 2E1 or 3A4/5 [56]. Delafloxacin
demonstrated mild induction of CYP3A4 at
clinically relevant concentrations in vitro;
however, it did not affect the Cmax and AUC
values for midazolam (a sensitive CYP3A4 sub-
strate) or its metabolite when administered to
healthy volunteers prior to midazolam admin-
istration [56]. Delafloxacin is a substrate of
breast cancer-related protein (BCRP) and a
potential substrate of P-glycoprotein [56].
However, only modest increases in delafloxacin
concentrations are anticipated when co-
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administered with BCRP or P-glycoprotein
inhibitors, and the clinical significance is
expected to be minimal [56]. The impact of
P-glycoprotein inducers, such as rifampicin, on
delafloxacin exposure has not been reported.
PLACE IN THERAPY
AND CONCLUSIONS
ABSSSI is a popular market-entry indication for
pharmaceutical companies developing new
antimicrobials targeting MRSA [64–67]. Dela-
floxacin recently received FDA approval in this
setting based on registry studies showing it to be
an effective and well-tolerated alternative [5].
Notable advantages of delafloxacin for the
treatment of ABSSSI include the availability of
both parenteral and oral formulations, a low
potential for drug–drug interactions and reas-
suring clinical and experimental data pertaining
to key class-adverse effects such as cardiotoxic-
ity and phototoxicity. With the availability of a
variety of new agents for the treatment of
ABSSSI, it will be important to determine which
agents are most suitable for specific patients on
the basis of coverage (broad versus narrow
spectrum), delivery (IV or PO) and potential for
adverse reactions and compliance (single versus
multiple daily dosing).
Of particular concern, fluoroquinolone use
has been associated with increased rates of col-
onization and infection with MRSA, ESBL-pro-
ducing Enterobacteriaceae and [5, 68–70] the
hypervirulent C. difficile RT027 strain [62, 70].
Recent international guidelines for the treat-
ment of a number of infectious diseases explic-
itly recognize the ecologic AEs of
fluoroquinolones as important factors in thera-
peutic decision-making and have called for
more restricted use of these agents [71, 72]. As
antibiotic innovation continues to move for-
ward, greater attention needs to be placed on
pinpointing unique properties of novel agents
to assist in determining their specific therapeu-
tic niche with respect to areas of unmet medical
need while limiting collateral damage.
There are many important areas of unmet
need in the treatment of gram-positive infec-
tions for which experimental data suggest the
distinctive structural and chemical properties of
delafloxacin may be harnessed to make it a
particularly valuable addition to the antibiotic
armamentarium. Improving long-term out-
comes in patients with biofilm-associated
infections is a critical unmet need, and dela-
floxacin’s potent activity against S. aureus
embedded in biofilm suggests a potential role in
this setting [41, 42]. Antibiotics that are capable
of eradicating intracellular non-replicating per-
sister bacteria in bone, prosthetic device-asso-
ciated infections and deep-seated abscesses are
clearly an unmet medical need, and dela-
floxacin’s excellent intracellular penetration,
especially in the acidic conditions that are
characteristic of these difficult to treat infec-
tions, points to another therapeutic niche [7]. A
potent oral agent would be particularly desir-
able in these settings because prolonged therapy
with IV antibiotics is often necessary but asso-
ciated with tremendous expense, inconve-
nience and harmful effects associated with
extended catheterization. The prospect of
combination therapy with delafloxacin and
rifampicin for these infections is intriguing, and
future research investigating the potential syn-
ergistic activity in biofilm models would be
valuable. Delafloxacin’s bactericidal activity
and excellent pulmonary penetration [36] are
also suggestive of a promising role against
pneumonia. The diminishing pool of effective
antibiotics for gonorrhea represents an urgent
public health threat [73]. Although a single oral
dose of delafloxacin was not sufficiently effec-
tive for uncomplicated gonorrhea infection, its
potent in vitro activity against this pathogen
[24] suggests that evaluations of alternative
dosing schedules would be worthwhile.
Struggles with resistance will not cease with
the availability of new antibiotics, and we must
learn how to optimally use and not abuse
promising new agents such as delafloxacin. An
oral antibiotic with in vitro activity against
MRSA, Pseudomonas spp., anaerobes, and atypi-
cal organisms will attract many prescribers, and
antimicrobial stewards will be tasked with
implementing it appropriately into practice. As
clinicians contemplate how to best incorporate
delafloxacin into infectious disease treatment
strategies, additional data pertaining to whether
Infect Dis Ther (2018) 7:197–217 213
the promising experimental data detailed in
this review do indeed translate into improved
outcomes for patient with difficult to treat
infections are greatly anticipated.
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